Table 1.
Baseline Characteristics of Subjects with Chronic Obstructive Pulmonary Disease, Stratified by Pulmonary Artery:Ascending Aorta Ratio Values, and Smokers with Normal Spirometry
| COPDGene NHWs |
COPDGene AAs |
ECLIPSE |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| COPD |
COPD |
COPD |
|||||||
| Characteristics | PA/A > 1 | PA/A ≤ 1 | Control Subjects | PA/A > 1 | PA/A ≤ 1 | Control Subjects | PA/A > 1 | PA/A ≤ 1 | Control Subjects |
| n | 535 | 2,128 | 2,534 | 260 | 494 | 1,749 | 471 | 1,153 | 178 |
| Age, yr | 64.2 (8.4) | 64.8 (8.1) | 59.5 (8.7) | 59.3 (8.1) | 58.7 (8.1) | 52.8 (6.0) | 63.7 (7.2) | 63.7 (7.0) | 57.5 (9.4) |
| Sex, % male | 42.1 | 59.1 | 49.3 | 40.0 | 62.6 | 58.1 | 62.2 | 67.1 | 57.9 |
| Pack-years | 54.6 (25.1) | 56.8 (28.6) | 37.8 (20.3) | 41.0 (22.3) | 43.3 (23.0) | 36.4 (20.1) | 47.8 (24.4) | 51.9 (28.6) | 32.1 (24.8) |
| Current smoker, % | 27.3 | 36.7 | 39.6 | 52.3 | 65.8 | 87.4 | 31.4 | 36.4 | 40.1 |
| FEV1 % predicted | 45.5 (17.4) | 50.8 (17.9) | 96.8 (11.0) | 47.1 (18.0) | 55.1 (16.7) | 98.4 (12.2) | 43.2 (14.8) | 49.5 (15.6) | 107.9 (13.7) |
| Spirometry grade, %* | |||||||||
| GOLD 2 | 41.3 | 53.5 | 46.2 | 62.8 | 29.8 | 46.8 | |||
| GOLD 3 | 37.2 | 30.7 | 33.1 | 28.1 | 50.0 | 41.3 | |||
| GOLD 4 | 21.5 | 15.8 | 20.8 | 9.1 | 20.2 | 11.9 | |||
| PA, cm | 3.3 (0.4) | 2.7 (0.4) | — | 3.3 (0.4) | 2.8 (0.4) | — | 3.5 (0.5) | 2.9 (0.4) | — |
| A, cm | 3.1 (0.3) | 3.3 (0.4) | — | 3.1 (0.4) | 3.2 (0.4) | — | 3.2 (0.4) | 3.4 (0.4) | — |
| PA/A | 1.07 (0.08) | 0.84 (0.10) | — | 1.09 (0.10) | 0.88 (0.09) | — | 1.10 (0.10) | 0.85 (0.10) | — |
| Exacerbation frequency per year | 1.32 (1.52) | 0.61 (1.10) | 1.06 (1.41) | 0.47 (1.04) | 1.14 (1.34) | 0.73 (1.16) | |||
Definition of abbreviations: AA, African American; COPD, chronic obstructive pulmonary disease; COPDGene, Genetic Epidemiology of COPD Study; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; FEV1, forced expiratory volume at 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NHW, non-Hispanic white; PA/A, ratio of the diameter of the main pulmonary artery (PA) at the level of its bifurcation and the diameter of the ascending aorta (A) in its maximum dimension measured by computed tomography.
Data are presented as mean (SD) or percentage, as appropriate.
For subjects with post-bronchodilator FEV1/forced vital capacity < 0.7; GOLD 2 = FEV1 ≥ 50% predicted and <80% predicted; GOLD 3 = FEV1 ≥ 30% predicted and <50% predicted; GOLD 4 = FEV1 < 30% predicted.